EP Patent

EP4205730A1 — Pharmaceutical composition of single dosage form for treating or preventing hypertension and hyperlipidemia

Assigned to Daewoong Pharmaceutical Co Ltd · Expires 2023-07-05 · 3y expired

What this patent protects

The present invention provides a single dosage form of pharmaceutical composition for treatment of hypertension and hyperlipidemia. According to the present invention, stability and uniform dissolution rates of drugs may be ensured by mixing compositions containing desired drugs …

USPTO Abstract

The present invention provides a single dosage form of pharmaceutical composition for treatment of hypertension and hyperlipidemia. According to the present invention, stability and uniform dissolution rates of drugs may be ensured by mixing compositions containing desired drugs and formulating the mixture into a single compartment form, whereby a manufacturing process becomes simple while reducing processing costs. Further, a formulation having biological equivalence to conventional single formulations may be obtained.

Drugs covered by this patent

Patent Metadata

Patent number
EP4205730A1
Jurisdiction
EP
Classification
Expires
2023-07-05
Drug substance claim
No
Drug product claim
No
Assignee
Daewoong Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.